GlassScriptPhysician profile
Bethany E Kinsey
NPI 1437546819
$33,308.98
in general payments reported to CMS, 2019-2025
23 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.97 · 2022: $413 · 2023: $2,728 · 2024: $15K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $2,892 · Consulting Fee: $2,688 · Travel and Lodging: $955 · Gift: $59.40 · Education: $41.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,247.00 |
| Food and Beverage | $2,892.30 |
| Consulting Fee | $2,688.00 |
| Travel and Lodging | $955.12 |
| Gift | $59.40 |
| Education | $41.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $31,054.77 | 2023-2025 | |
| Mannkind Corporation | $643.11 | 2022-2024 | Afrezza |
| Tandem Diabetes Care, INC. | $332.94 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $198.61 | 2023-2024 | Korlym |
| Novo Nordisk INC | $176.18 | 2022-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $130.73 | 2022-2024 | Freestyle Libre 3 |
| Insulet Corporation | $102.98 | 2023-2024 | Omnipod |
| Kyowa Kirin, INC. | $84.12 | 2024 | Crysvita |
| Amgen INC. | $74.70 | 2025 | Tepezza |
| Dexcom, INC. | $68.18 | 2022-2024 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $64.24 | 2023 | Tepezza |
| Medtronic, INC. | $60.91 | 2024 | Intellis Adaptivestim, Minimed 780g |
| Cequr Corporation | $58.25 | 2023-2024 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $51.46 | 2024 | Recorlev |
| Ascensia Diabetes Care US INC. | $40.29 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $34.50 | 2022 | |
| Amneal Pharmaceuticals LLC | $32.24 | 2023 | Unithroid |
| Pfizer INC. | $20.42 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.13 | 2022 | |
| Abbvie INC. | $17.41 | 2023 | |
| Lilly USA, LLC | $16.72 | 2023 | Jardiance |
| Recordati_rare_diseases_inc. | $14.52 | 2024 | Isturisa, Signifor Lar |
| Ibsa Pharma INC. | $13.57 | 2024 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Kinsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.